ORPHA:448267
Regressive spondylometaphyseal dysplasia
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
6
21.7th percentile
Trials
0
Interventional, condition-specific
Researchers
33
Distinct authors in sample
Gene link
LBR
Strong
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, primary bone characterized by mild short stature, rhizomelic shortening of the arms and legs, bowing of long bones with widened and irregular metaphyses, thoracolumbar kyphosis, and metacarpal shortening. A marked improvement of the radiologic skeletal features is typical. Pelger-Huet anomaly (i.e. dumbbell shape bilobed nuclei of neutrophils) is a characteristic hematological feature of this disease.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018663
- OMIM:618019
- UMLS:C4747922
Additional Mondo synonyms (2)
Pelger-Huet anomaly with mild skeletal anomalies · regressive spondylometaphyseal dysplasia
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Strong — LBR
- LiteraturePresent
6 matched papers (6 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (LBR).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
6
6 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
6 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
6 in the last 10 years · high confidence · 21.7th percentile (publications denominator)
Phrase hits: 6 · MeSH hits: 0
Who's working on it?
33
Distinct author names in 6 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Altunoglu U1 paper · 2022
Department of Medical Genetics, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
Papers in Europe PMC - 02Berg JS1 paper · 2018
Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Papers in Europe PMC - 03Borah S1 paper · 2022
National Institute of Immunohaematology, Mumbai, Maharashtra, India.
Papers in Europe PMC - 04Bosco M1 paper · 2019
Pathological Anatomy and Histology Unit, San Lazzaro Hospital, Alba, Italy.
Papers in Europe PMC - 05Brown E1 paper · 2020
Victorian Clinical Genetics Services, Royal Women's Hospital, Melbourne, VIC, Australia.
Papers in Europe PMC - 06Brusco A1 paper · 2019
Department of Medical Sciences, University of Torino, Torino, Italy.
Papers in Europe PMC - 07Brussino A1 paper · 2019
Department of Medical Sciences, University of Torino, Torino, Italy.
Papers in Europe PMC - 08Dhanasekaran K1 paper · 2022
Regional Centre for Biotechnology, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Papers in Europe PMC - 09Dirimtekin E1 paper · 2025
Department of Medical Genetics, School of Medicine, Marmara University, Istanbul, Turkey.
Papers in Europe PMC - 10Geckinli BB1 paper · 2025
Department of Medical Genetics, School of Medicine, Marmara University, Istanbul, Turkey.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
Broader category spondylometaphyseal dysplasia also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Broader category: spondylometaphyseal dysplasia
0
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Parent-category matching found a broader label but no interventional trials under it. How we count trials.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Regressive spondylometaphyseal dysplasia" OR "Pelger-Huet anomaly with mild skeletal anomalies"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Regressive spondylometaphyseal dysplasia" OR "Pelger-Huet anomaly with mild skeletal anomalies" OR "LBR"
Recall-expansion terms: LBR
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"spondylometaphyseal dysplasia"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T16:36:56.437Z